These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29356963)

  • 1. Pathologic conditions of hard tissue: role of osteoclasts in osteolytic lesion.
    Kitazawa R; Haraguchi R; Fukushima M; Kitazawa S
    Histochem Cell Biol; 2018 Apr; 149(4):405-415. PubMed ID: 29356963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
    Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
    Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
    Kitazawa S; Kitazawa R
    J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DGKζ Downregulation Enhances Osteoclast Differentiation and Bone Resorption Activity Under Inflammatory Conditions.
    Iwazaki K; Tanaka T; Hozumi Y; Okada M; Tsuchiya R; Iseki K; Topham MK; Kawamae K; Takagi M; Goto K
    J Cell Physiol; 2017 Mar; 232(3):617-624. PubMed ID: 27312515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is vitamin D deficiency behind the scenes for high incidence of Giant cell tumor amongst the Indian population? Unraveling the vitamin D - RANKL association.
    Gundavda MK; Agarwal MG; Reddy R; Wagh Y; Ghanate V
    Med Hypotheses; 2019 Feb; 123():67-71. PubMed ID: 30696596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades.
    Song F; Wei C; Zhou L; Qin A; Yang M; Tickner J; Huang Y; Zhao J; Xu J
    J Cell Physiol; 2018 Feb; 233(2):1723-1735. PubMed ID: 28681916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canonical and non-canonical pathways of osteoclast formation.
    Knowles HJ; Athanasou NA
    Histol Histopathol; 2009 Mar; 24(3):337-46. PubMed ID: 19130404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
    Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
    Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.
    Farrugia AN; Atkins GJ; To LB; Pan B; Horvath N; Kostakis P; Findlay DM; Bardy P; Zannettino AC
    Cancer Res; 2003 Sep; 63(17):5438-45. PubMed ID: 14500379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
    Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
    Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The participation of RANK, RANKL and OPG in tumor osteolysis].
    Stanisławowski M; Kmieć Z
    Postepy Hig Med Dosw (Online); 2009 May; 63():234-41. PubMed ID: 19502684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
    Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
    Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alexidine Dihydrochloride Attenuates Osteoclast Formation and Bone Resorption and Protects Against LPS-Induced Osteolysis.
    Zhu X; Gao J; Ng PY; Qin A; Steer JH; Pavlos NJ; Zheng MH; Dong Y; Cheng TS
    J Bone Miner Res; 2016 Mar; 31(3):560-72. PubMed ID: 26363136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.
    Suda T; Takahashi N; Udagawa N; Jimi E; Gillespie MT; Martin TJ
    Endocr Rev; 1999 Jun; 20(3):345-57. PubMed ID: 10368775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel inhibits osteoclast formation and bone resorption via influencing mitotic cell cycle arrest and RANKL-induced activation of NF-κB and ERK.
    Ang ES; Pavlos NJ; Chim SM; Feng HT; Scaife RM; Steer JH; Zheng MH; Xu J
    J Cell Biochem; 2012 Mar; 113(3):946-55. PubMed ID: 22034016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.